SEC Tracker
Get the app

Spyre Therapeutics SYRE

Spyre Therapeutics Q2 FY25: net loss $36.7M

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q
Exhibit 10.1
Material contract

Key figures from this report

These are the numbers Spyre Therapeutics reported for Q2 FY25, the quarter ended Jun 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$36.7MAgainst −$38.8M in Q2 FY2410-Q income statement, on EDGAR
  2. Cash and cash equivalents$81.7M+81% from $45.1M in Q2 FY24Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  3. Cash from operations−$46.6MAgainst −$62.2M in Q2 FY2410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Spyre Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Schrodinger SDGR public float $1.1B, Jun 30, 2025
  2. Mannkind MNKD public float $1.1B, Jun 30, 2025
  3. Novavax NVAX public float $1.0B, Jun 30, 2025
  4. Harrow HROW public float $1.0B, Jun 30, 2025
  5. Aurinia Pharmaceuticals AUPH public float $1.0B, Jun 30, 2025